Xue Mei
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xue Mei has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
Xiaojing Song
College of Pharmacy, North Sichuan Medical College
2 shared publicationsXiaoqin Chen
College of Pharmacy, North Sichuan Medical College
2 shared publicationsBaiqiang Wang
Department of Pharmacy, Affiliated Hospital of North Sichuan Medical College, Nanchong, China
1 shared publicationBo Huang
School of Clinical Medicine and Affiliated Hospital, North Sichuan Medical College
1 shared publication- Chunyan Yang
School of Pharmacy, Institute of Material Medica, North Sichuan Medical College, Nanchong 637100, China
1 shared publication - Chunyang Zhou
School of Pharmacy, Institute of Material Medica, North Sichuan Medical College, Nanchong, China
1 shared publication
Latest Publications
- Open Access
- 19 June 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1840918
Development and validation of a predictive model for forceps delivery risk in term singleton primiparas for early identification and labor management optimization
Introduction: This study aimed to establish and validate a predictive model for forceps-assisted delivery in term singleton primiparas during the early second stage of labor, enabling early identification of high-risk cases and targeted intrapartum care to reduce maternal and neonatal risks associated with prolonged labor. Materials and methods: The study retrospectively analyzed clinical data from pregnant women who delivered at The Second People’s Hospital of Yibin City between January 2017 and December 2024. Term singleton primiparas who underwent forceps delivery were designated as the forceps delivery group ( n = 346), while each corresponding case of spontaneous vaginal delivery (SVD) was included in the vaginal delivery group ( n = 346) using adjacent case matching. Maternal, fetal, and labor characteristics were collected and compared between groups. Univariate and multivariate logistic regression analyses were conducted to identify independent risk factors for forceps delivery and to construct a predictive model. Model performance was comprehensively evaluated in terms of discrimination, calibration, and clinical utility using the area under the receiver operating characteristic curve (AUC), the Hosmer–Lemeshow test, the Brier score, and clinical decision curve analysis (DCA). Results: Independent risk factors for forceps delivery in term singleton primiparas identified at the onset of the second stage of labor included: pre-delivery body mass index (BMI) ≥ 28 kg/m 2 , fetal abdominal circumference ≥ 340 mm, grade II or III meconium-stained fluid (MSF), non-occipital anterior (OA) fetal position, and active phase duration ≥ 120 min. This predictive model for early risk identification during the second stage of labor achieved an AUC of 0.775 (95% CI: 0.741–0.810), with an optimal cutoff value of 0.413, corresponding to a sensitivity of 0.688 and a specificity of 0.725. The Hosmer–Lemeshow test indicated a good model fit. After 500 internal bootstrap validations, the corrected C-index was 0.771. The model demonstrated acceptable calibration and provided a net benefit over the treat-all strategy for clinically plausible threshold probabilities up to 0.35. Conclusion: The proposed model, based on routine intrapartum predictors at the onset of the second stage, enables early risk stratification for forceps delivery in term singleton primiparas and supports anticipatory intrapartum planning. Further prospective, multicenter external validation is warranted to determine its real-world clinical impact and generalizability.
- 19 June 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1840918
Open AccessDevelopment and validation of a predictive model for forceps delivery risk in term singleton primiparas for early identification and labor management optimization
Introduction: This study aimed to establish and validate a predictive model for forceps-assisted delivery in term singleton primiparas during the early second stage of labor, enabling early identification of high-risk cases and targeted intrapartum care to reduce maternal and neonatal risks associated with prolonged labor. Materials and methods: The study retrospectively analyzed clinical data from pregnant women who delivered at The Second People’s Hospital of Yibin City between January 2017 and December 2024. Term singleton primiparas who underwent forceps delivery were designated as the forceps delivery group ( n = 346), while each corresponding case of spontaneous vaginal delivery (SVD) was included in the vaginal delivery group ( n = 346) using adjacent case matching. Maternal, fetal, and labor characteristics were collected and compared between groups. Univariate and multivariate logistic regression analyses were conducted to identify independent risk factors for forceps delivery and to construct a predictive model. Model performance was comprehensively evaluated in terms of discrimination, calibration, and clinical utility using the area under the receiver operating characteristic curve (AUC), the Hosmer–Lemeshow test, the Brier score, and clinical decision curve analysis (DCA). Results: Independent risk factors for forceps delivery in term singleton primiparas identified at the onset of the second stage of labor included: pre-delivery body mass index (BMI) ≥ 28 kg/m 2 , fetal abdominal circumference ≥ 340 mm, grade II or III meconium-stained fluid (MSF), non-occipital anterior (OA) fetal position, and active phase duration ≥ 120 min. This predictive model for early risk identification during the second stage of labor achieved an AUC of 0.775 (95% CI: 0.741–0.810), with an optimal cutoff value of 0.413, corresponding to a sensitivity of 0.688 and a specificity of 0.725. The Hosmer–Lemeshow test indicated a good model fit. After 500 internal bootstrap validations, the corrected C-index was 0.771. The model demonstrated acceptable calibration and provided a net benefit over the treat-all strategy for clinically plausible threshold probabilities up to 0.35. Conclusion: The proposed model, based on routine intrapartum predictors at the onset of the second stage, enables early risk stratification for forceps delivery in term singleton primiparas and supports anticipatory intrapartum planning. Further prospective, multicenter external validation is warranted to determine its real-world clinical impact and generalizability.
- Open Access
- 11 May 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1820545
Bridging the gap between AI and traditional teaching methods in medical education: opportunities, challenges, and solutions
The integration of artificial intelligence (AI) into medical education has given rise to the innovative “AI + X” model, in which X refers to core disciplines such as clinical medicine, pharmacy, and nursing. Although this model enables personalized learning and immersive practical training, its widespread implementation also raises urgent ethical challenges. This study identifies key risks in AI-enabled medical education, including algorithmic bias that may shape students’ professional perceptions and data privacy breaches resulting from unauthorized data use. A critical contribution of this study is the clear differentiation between generative AI tools (e.g., ChatGPT) and clinically validated AI systems (e.g., FDA-cleared radiology diagnostic tools), a distinction often overlooked in current curricula. The paper further examines the risks of using AI as a decision-support or moral guide, which may weaken humanistic values and professional autonomy, and discusses how superficial AI use may misalign with educators’ roles, impair the patient-physician relationship, and foster student over-reliance. To address these challenges, we propose strengthening oversight of data processing and storage, improving transparency in AI decision-making, preserving human agency, fostering emotional engagement, enhancing educators’ integrated teaching competencies, and cultivating students’ critical thinking. Ultimately, the responsible integration of AI into medical education requires collaborative action from all stakeholders and should be guided by a three-dimensional ethical governance framework encompassing technological ethics, educational philosophy, and medical humanities.
- 11 May 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1820545
Open AccessBridging the gap between AI and traditional teaching methods in medical education: opportunities, challenges, and solutions
The integration of artificial intelligence (AI) into medical education has given rise to the innovative “AI + X” model, in which X refers to core disciplines such as clinical medicine, pharmacy, and nursing. Although this model enables personalized learning and immersive practical training, its widespread implementation also raises urgent ethical challenges. This study identifies key risks in AI-enabled medical education, including algorithmic bias that may shape students’ professional perceptions and data privacy breaches resulting from unauthorized data use. A critical contribution of this study is the clear differentiation between generative AI tools (e.g., ChatGPT) and clinically validated AI systems (e.g., FDA-cleared radiology diagnostic tools), a distinction often overlooked in current curricula. The paper further examines the risks of using AI as a decision-support or moral guide, which may weaken humanistic values and professional autonomy, and discusses how superficial AI use may misalign with educators’ roles, impair the patient-physician relationship, and foster student over-reliance. To address these challenges, we propose strengthening oversight of data processing and storage, improving transparency in AI decision-making, preserving human agency, fostering emotional engagement, enhancing educators’ integrated teaching competencies, and cultivating students’ critical thinking. Ultimately, the responsible integration of AI into medical education requires collaborative action from all stakeholders and should be guided by a three-dimensional ethical governance framework encompassing technological ethics, educational philosophy, and medical humanities.
- Open Access
- 22 December 2025
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 82 (1) , 18
Itraconazole-associated adverse events in fungal infections: a study of a large real-world sample based on the FAERS database (2019–2024)
Background Itraconazole (ITZ) is a broad-spectrum antifungal agent widely used for the treatment and prevention of fungal infections, particularly systemic and cutaneous infections. Although considered safe, recent clinical reports and studies have indicated that ITZ can cause a range of adverse events (AEs), particularly affecting vital organs such as the heart and liver. The objective of this study was to evaluate ITZ-associated adverse events by conducting data mining using the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) to assess potential safety risks. Methods A retrospective pharmacovigilance analysis was performed using FAERS data from Q1 2019 to Q2 2024. Four disproportionality algorithms were applied to identify significant signals related to ITZ-AEs, including the Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Empirical Bayes Geometric Mean (EBGM). Results From a total of 6,191,576 case reports in FAERS, 1,041 reports identified ITZ as the primary suspected (PS) agent linked to AEs. A total of 323 ITZ-associated AEs were identified across 16 organ systems at the preferred terms (PTs) level. Expected AEs, including general disorders, administration site conditions, cardiac disorders, and hepatobiliary disorders, were identified, consistent with the drug label. In addition, 31 unexpected AEs were detected, including left ventricular dysfunction (39 cases, EBGM 31.81/EBGM05 15.83), myositis (38 cases, EBGM 29.75/EBGM05 15.94), both associated with vascular disorders at the system organ class (SOC) level. These findings suggest the presence of potential adverse effects that are not currently addressed in the drug’s labeling. Conclusions This study identified 31 novel and unexpected AE signals associated with ITZ, which are consistent with clinical observations. These findings provide new insights into the safety profile of ITZ, highlighting the need for increased vigilance in clinical practice regarding its potential adverse effects. Future studies should validate these signals and explore their clinical implications to enhance drug safety monitoring and labeling updates.
- 22 December 2025
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 82 (1) , 18
Open AccessItraconazole-associated adverse events in fungal infections: a study of a large real-world sample based on the FAERS database (2019–2024)
Background Itraconazole (ITZ) is a broad-spectrum antifungal agent widely used for the treatment and prevention of fungal infections, particularly systemic and cutaneous infections. Although considered safe, recent clinical reports and studies have indicated that ITZ can cause a range of adverse events (AEs), particularly affecting vital organs such as the heart and liver. The objective of this study was to evaluate ITZ-associated adverse events by conducting data mining using the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) to assess potential safety risks. Methods A retrospective pharmacovigilance analysis was performed using FAERS data from Q1 2019 to Q2 2024. Four disproportionality algorithms were applied to identify significant signals related to ITZ-AEs, including the Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Empirical Bayes Geometric Mean (EBGM). Results From a total of 6,191,576 case reports in FAERS, 1,041 reports identified ITZ as the primary suspected (PS) agent linked to AEs. A total of 323 ITZ-associated AEs were identified across 16 organ systems at the preferred terms (PTs) level. Expected AEs, including general disorders, administration site conditions, cardiac disorders, and hepatobiliary disorders, were identified, consistent with the drug label. In addition, 31 unexpected AEs were detected, including left ventricular dysfunction (39 cases, EBGM 31.81/EBGM05 15.83), myositis (38 cases, EBGM 29.75/EBGM05 15.94), both associated with vascular disorders at the system organ class (SOC) level. These findings suggest the presence of potential adverse effects that are not currently addressed in the drug’s labeling. Conclusions This study identified 31 novel and unexpected AE signals associated with ITZ, which are consistent with clinical observations. These findings provide new insights into the safety profile of ITZ, highlighting the need for increased vigilance in clinical practice regarding its potential adverse effects. Future studies should validate these signals and explore their clinical implications to enhance drug safety monitoring and labeling updates.
- Open Access
- 10 December 2025
- Published by Springer Nature in Molecular Neurobiology
- Vol. 63 (1) , 278
Unraveling Cannabidiol's Dual Modulatory Role in Schizophrenia: Network Pharmacology and In Vivo Validation of Neuroinflammatory and Behavioral Modulation
Schizophrenia (SCZ), a chronic psychiatric disorder, is characterized by cognitive impairment, hallucinations, and delusions, with current antipsychotic treatments offering limited efficacy and considerable side effects. Cannabidiol (CBD), a nonpsychoactive compound from Cannabis sativa, has shown promise in treating neurological and psychiatric conditions, though its precise mechanisms in schizophrenia remain unclear. Using network pharmacology, this study predicts CBD's targets and pathways in schizophrenia, highlighting LPS-induced neuroinflammation and implicating 5-HT1AR-MAPK signaling as one potential contributor. In vitro, CBD (10 mg/kg, i.p.) treatment significantly reduced pro-inflammatory cytokines (e.g., NO, IL-1β, IL-6, TNF-α) and modulated the 5HT1AR-MAPK pathway, including increased 5HT1AR expression and decreased MAPK/ERK1/2 phosphorylation (p < 0.05). In vivo, CBD alleviated SCZ-like symptoms in a ketamine-induced animal model, reducing anxiety in the open field (p < 0.01) and elevated plus maze tests (p < 0.01), improving spatial memory in the Y-maze (p < 0.01) and social behavior (p < 0.0001) after 5 consecutive days of treatment. Critically, we validated CBD's central anti-inflammatory effects by demonstrating reduced pro-inflammatory cytokine levels in both plasma and brain tissues (p < 0.05). Further correlation analysis established a direct link between brain cytokine suppression and behavioral improvements, integrating in vitro findings from BV2 microglial cells with in vivo neuroinflammatory and behavioral outcomes. These findings suggest the potential therapeutic benefits of CBD for SCZ, though further research, particularly clinical trials, is required to validate its efficacy and establish it as a novel therapeutic strategy.
- 10 December 2025
- Published by Springer Nature in Molecular Neurobiology
- Vol. 63 (1) , 278
Open AccessUnraveling Cannabidiol's Dual Modulatory Role in Schizophrenia: Network Pharmacology and In Vivo Validation of Neuroinflammatory and Behavioral Modulation
Schizophrenia (SCZ), a chronic psychiatric disorder, is characterized by cognitive impairment, hallucinations, and delusions, with current antipsychotic treatments offering limited efficacy and considerable side effects. Cannabidiol (CBD), a nonpsychoactive compound from Cannabis sativa, has shown promise in treating neurological and psychiatric conditions, though its precise mechanisms in schizophrenia remain unclear. Using network pharmacology, this study predicts CBD's targets and pathways in schizophrenia, highlighting LPS-induced neuroinflammation and implicating 5-HT1AR-MAPK signaling as one potential contributor. In vitro, CBD (10 mg/kg, i.p.) treatment significantly reduced pro-inflammatory cytokines (e.g., NO, IL-1β, IL-6, TNF-α) and modulated the 5HT1AR-MAPK pathway, including increased 5HT1AR expression and decreased MAPK/ERK1/2 phosphorylation (p < 0.05). In vivo, CBD alleviated SCZ-like symptoms in a ketamine-induced animal model, reducing anxiety in the open field (p < 0.01) and elevated plus maze tests (p < 0.01), improving spatial memory in the Y-maze (p < 0.01) and social behavior (p < 0.0001) after 5 consecutive days of treatment. Critically, we validated CBD's central anti-inflammatory effects by demonstrating reduced pro-inflammatory cytokine levels in both plasma and brain tissues (p < 0.05). Further correlation analysis established a direct link between brain cytokine suppression and behavioral improvements, integrating in vitro findings from BV2 microglial cells with in vivo neuroinflammatory and behavioral outcomes. These findings suggest the potential therapeutic benefits of CBD for SCZ, though further research, particularly clinical trials, is required to validate its efficacy and establish it as a novel therapeutic strategy.